GSK plc (GSK)

NYSE: GSK · IEX Real-Time Price · USD
36.25
-0.09 (-0.25%)
At close: Sep 29, 2023, 4:00 PM
36.28
+0.03 (0.08%)
After-hours: Sep 29, 2023, 7:02 PM EDT
-0.25%
Market Cap 74.22B
Revenue (ttm) 37.13B
Net Income (ttm) 19.53B
Shares Out 2.05B
EPS (ttm) 9.21
PE Ratio 11.81
Forward PE 9.80
Dividend $1.45 (3.99%)
Ex-Dividend Date Aug 17, 2023
Volume 4,184,339
Open 36.53
Previous Close 36.34
Day's Range 36.09 - 36.67
52-Week Range 29.38 - 39.74
Beta 0.30
Analysts n/a
Price Target n/a
Earnings Date Nov 1, 2023

About GSK

GSK plc, together with its subsidiaries, engages in the research, development and manufacture of vaccines and specialty medicines to prevent and treat disease in the United Kingdom, the United States, and internationally. It operates through four segments: Pharmaceuticals, Pharmaceuticals R&D, Vaccines, and Consumer Healthcare. The company offers pharmaceutical products comprising medicines in the therapeutic areas, such as infectious disease, HIV, immunology and respiratory, and oncology. The company was formerly known as GlaxoSmithKline plc a... [Read more]

Sector Healthcare
Founded 1715
Employees 69,400
Stock Exchange NYSE
Ticker Symbol GSK
Full Company Profile

Financial Performance

In 2022, GSK plc's revenue was 29.32 billion, an increase of 18.74% compared to the previous year's 24.70 billion. Earnings were 14.96 billion, an increase of 241.07%.

Financial numbers in GBP Financial Statements

News

GSK lifts growth ambitions for HIV business on long-acting drug

GSK on Thursday lifted its medium-term growth forecast for its HIV drugs business ViiV, encouraged by strong sales of long-acting injections that aim to replace daily pills for preventing and treating...

3 days ago - Reuters

Explainer: What you need to know about RSV and the new vaccines

Advisers to the U.S. Centers for Disease Control and Prevention (CDC) are meeting on Friday to discuss recommendations for use of the first vaccine for respiratory syncytial virus (RSV) approved for p...

Other symbols: PFE
9 days ago - Reuters

European Commission authorises GSK's HIV prevention drug

The European Commission has authorised GSK's HIV-focused unit ViiV Healthcare's cabotegravir long-acting injectable and tablets, the British drugmaker said on Tuesday.

12 days ago - Reuters

Incyte shares drop after FDA approves GSK's competing blood-cancer treatment

Incyte Corp. INCY, -1.47% shares dropped more than 5% premarket on Monday after the U.S. Food and Drug Administration on Friday approved a GSK PLC GSK, +0.11% blood-cancer treatment, Ojjaara, that wil...

Other symbols: INCY
13 days ago - Market Watch

US FDA approves GSK's anemia treatment

British drugmaker GSK Plc said on Friday the U.S. Food and Drug Administration had approved its experimental drug to treat anemic patients with a type of bone marrow cancer called myelofibrosis.

15 days ago - Reuters

EU regulator recommends to stop sale of GSK's blood cancer drug

The European Medicines Agency's human medicines committee on Friday recommended against renewal of the conditional marketing authorisation for GSK's blood cancer drug Blenrep.

16 days ago - Reuters

GSK and Earvin “Magic” Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA Locations

PHILADELPHIA--(BUSINESS WIRE)--GSK and Earvin “Magic” Johnson to Host Community Awareness Events about Older Adult Risk for RSV at YMCA Locations.

26 days ago - Business Wire

GSK Announces AREXVY, Its Respiratory Syncytial Virus (RSV) Vaccine, Is Now Available at All Major US Retail Pharmacies

PHILADELPHIA--(BUSINESS WIRE)-- #AREXVY--GSK announces AREXVY, its respiratory syncytial virus (RSV) vaccine, is now available at all major US retail pharmacies.

6 weeks ago - Business Wire

Pfizer Sued By GSK Over Alleged Patent Infringement For Its RSV Vaccine

British drugmaker GlaxoSmithKline is accusing Pfizer of infringing on four of its patents in its RSV vaccine.

Other symbols: PFE
2 months ago - Forbes

GSK sues Pfizer in U.S. court for patent infringement over RSV vaccine

Both RSV vaccines were approved by the U.S. Food and Drug Administration for use in adults 60 and above.

Other symbols: PFE
2 months ago - CNBC

GSK sues Pfizer in US for patent infringement over RSV vaccine

British biopharmaceutical giant GSK sued Pfizer in Delaware federal court on Wednesday, accusing Pfizer's respiratory syncytial virus (RSV) vaccine Abrysvo of violating GSK's patent rights in its riva...

Other symbols: PFE
2 months ago - Reuters

GSK chief says RSV vaccine will start off slower than shingles shot – but will drive future sales

London-based GSK is preparing to roll out its RSV vaccine in the U.S. and European Union this fall, when the disease begins to spread at higher levels.

2 months ago - CNBC

India's GlaxoSmithKline Pharma posts rise in Q1 profit on steady vaccine business

GlaxoSmithKline Pharmaceuticals , the Indian unit of UK's GSK plc , posted an 11% rise in first-quarter profit on Wednesday, buoyed by strong demand for its vaccines.

2 months ago - Reuters

GSK expects RSV vaccine uptake will be slower than for its shingles vaccine-CEO

GSK does not expect uptake of its RSV vaccine will initially be as swift as it was for its blockbuster shingles vaccine, though the company is confident in its new inoculation, Chief Executive Emma Wa...

2 months ago - Reuters

GSK raises 2023 outlook boosted by vaccine, HIV drug sales

GSK raised its full-year profit and sales guidance on Wednesday after its second-quarter earnings beat expectations, helped by strong sales of its shingles vaccine Shingrix and HIV medicines.

2 months ago - Reuters

GSK's HIV prevention drug gets European marketing nod

GSK Plc said on Monday that its HIV-focused unit ViiV Healthcare's cabotegravir injected drug and tablets got marketing authorisation from the European Medicines Agency.

2 months ago - Reuters

GSK Grants LimmaTech Biologics License to Develop and Commercialize Shigella Vaccine

SCHLIEREN, Switzerland--(BUSINESS WIRE)--LimmaTech Biologics AG (“LimmaTech Bio”), a clinical-stage biotech company developing vaccines for the prevention of life-threatening diseases, signed an in-li...

2 months ago - Business Wire

GSK is first to ship influenza vaccine doses for the 2023-24 flu season in US

PHILADELPHIA--(BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced it has started shipping doses of its quadrivalent influenza vaccines to US healthcare providers and pharmacies in preparation for...

2 months ago - Business Wire

Elsie Biotechnologies Announces Collaboration with GSK to Accelerate Oligonucleotide Discovery Technologies

SAN DIEGO--(BUSINESS WIRE)-- #mRNA--Elsie Biotechnologies, Inc., a biopharmaceutical company unlocking the full potential of oligonucleotide therapeutics, announced today a research collaboration agre...

2 months ago - Business Wire

UK regulator authorizes GSK's RSV vaccine

Britain's medicines regulator authorized GSK's vaccine for respiratory syncytial virus (RSV) for older adults, the drugmaker said on Monday.

2 months ago - Reuters

CDC recommends RSV vaccines from Pfizer, GSK for adults 60 and older

The CDC said the shots from Pfizer and GSK are expected to be available this fall, when RSV – along with Covid and the flu – begins to spread at higher levels.

Other symbols: PFE
3 months ago - CNBC

US CDC recommends use of new Pfizer, GSK vaccines for RSV in older adults

The director of the U.S. Centers for Disease Control and Prevention (CDC) signed off on Thursday on the use of new vaccines from Pfizer and GSK to prevent severe respiratory syncytial virus (RSV) infe...

Other symbols: PFE
3 months ago - Reuters

Drugmaker GSK Is Becoming a Healthier Value Stock

Like most stocks during the dot-com bubble, GSK PLC NYSE: GSK partied like it was 1999. In the two decades since, missteps and competitive pressures slashed roughly 50% from the U.K. pharmaceutical co...

3 months ago - MarketBeat

GSK's gonorrhoea vaccine receives FDA's 'fast-track' designation

GSK's vaccine candidate to treat sexually transmitted infection gonorrhoea has been granted a fast-track designation by the U.S. Food and Drug Administration (FDA), the British drugmaker said on Tuesd...

3 months ago - Reuters

GSK Settles Zantac Cancer Lawsuit Set to Go to Trial Next Month

American depositary receipts of GSK jumped after the U.K.-based biopharma company said it had reached a settlement in a lawsuit accusing the firm's discontinued heartburn medicine, Zantac, of causing ...

3 months ago - Investopedia